Neoadjuvant immunotherapy improves outcomes in high-risk melanoma patients.

Published Date: 02 Mar 2023

High-risk melanoma patients who received the drug pembrolizumab before or after surgery to remove the cancer had a higher risk of developing melanoma than those who did not have a similar condition that eliminated cancer cells.

Read Full News

Latest News



Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

How access to specialized cancer centers affects glioblastoma outcomes

2.

High Success Rate With Conversion Therapy for Unresectable Gastroesophageal Cancer

3.

New policy review highlights the importance of health-related quality of life in advanced cancer

4.

Results for Prostate Cancer Are Associated With PSA Nadir 6 Months After Primary RT.

5.

Healthy weight loss could lower your odds for cancer


© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot